Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | Analysis of JAK inhibitors and risk of secondary B-cell lymphomas in MPN patients

Naveen Pemmaraju • 15 Jun 2019
EHA 2019
Myeloproliferative Neoplasms

Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses his group’s latest work on JAK inhibitors and the risk of secondary B-cell lymphomas in patients with myeloproliferative neoplasms (MPNs). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Naveen Pemmaraju

The value and interactive format of the MPN Workshop of the Carolinas 6:05
The value and interactive format of the MPN Workshop of the Carolinas
Naveen Pemmaraju et al. • 22 Aug 2025
An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN 2:06
An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN
Naveen Pemmaraju • 15 Jun 2025
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more 1:55
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more
Naveen Pemmaraju • 31 May 2025
A review of the clinical safety and efficacy of ruxolitinib 10 years after its approval for PV 2:17
A review of the clinical safety and efficacy of ruxolitinib 10 years after its approval for PV
Naveen Pemmaraju • 31 May 2025

Related Videos

Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US 2:03
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US
Aaron Gerds • 5 Dec 2025
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat 2:12
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat
Prithviraj Bose • 7 Dec 2025
Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs 2:40
Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs
Anand Patel • 25 Nov 2025
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes 4:47
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes
Daniel Wiseman • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals